Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC

Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato – 27 April 2022 – The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) ha

Reply

Nupur Sharma, Manisha Yadav, Gaurav Tripathi, Babu Mathew, Vasundhra Bindal, Sanyam Falari, Viniyendra Pamecha, Jaswinder Singh Maras – 27 April 2022

Subscribe to